logo/base Created with Sketch.

Guided VCTE™

Seamless liver health assessment for all

As a leader in liver health, we have elevated our core liver elastography technology to the next level with the introduction of Guided VCTE™ – our Next-Generation FibroScan® technology.


Faster examinations with improved guidance

Guided VCTE™ indicators

Two new visual indicators allow operators to quickly identify
the optimal measurement location.1

Computed by a continuous vibration of the probe transducer, these indicators intuitively guide the operator throughout the entire duration of the exam.


Time savings for all adult patient morphologies

With Guided VCTE™, 96% of patients can be scanned in less than 4 minutes,
including patients with BMI>30.

Simplified scanning for a strengthened user experience

AutoScan: New efficiency feature

Based on the Guided VCTE™ indicators, AutoScan automatically triggers
10 valid measurements through a single click, enabling streamlined scanning
and a likely improved operator experience.

Guided VCTE™ includes all SmartExam features

Improved reliability in the diagnosis and monitoring of steatosis
with Continuous CAP™ to decrease variability by 50%2.

Extended usage among patients with severe obesity with deeper assessment of liver fibrosis and steatosis as the maximum probe-to-capsula distance is increased by 28%*.

Automated features such as CAP™ validity criteria and automatic measurement depth selection to adapt to patient’s morphology



What our users say

Guided VCTE™ is endorsed by healthcare professionals


Guided VCTE™ helps improve operator efficiency and perhaps standardize their performance. We expect that Guided VCTE™ features will improve the reliability of LSM without prolonging the study duration, even in patients with MASLD.

Dr. Raj Vuppalanchi | Professor of Medicine, Director of Hepatology and Associate Program Director | Indiana University School of Medicine


Guided VCTE™ technology has significantly improved the operator’s confidence that the probe is in the right place over the liver, excluding either lung or rib artifact. This will also enhance reliability when performing sequential scans on the same patient.

Dr. Martin Grajower | MD, FACP, FACE | Endocrinologist, Clinical Professor of Medicine | Albert Einstein College of Medicine


The addition of Guided VCTE™ is practice changing as it provides benefits to the provider and operator. Our clinical practice is able to be more efficient with the combination of a faster scan, providing my operators with easier localization and consistent measurements. The new reports contain a more refined image facilitating my interpretations. Guided VCTE™ has augmented both our comfort and confidence in measurement accuracy when diagnosing our patients with liver disease.

Dr. Tejas Joshi | Hepatologist, Director of Liver Diseases & Associate Professor | Marshall University School of Medicine

chevron chevron

The Technology Behind Guided VCTE™

This white paper provides a technology overview of Guided VCTE™
and its associated benefits.

Our solutions come with a dedicated support

From installation, to training and local support, we provide you with the highest quality of services.

* Without SmartExam, the maximum recommended Probe-to-Capsula distance (PCD) is 35 mm. With SmartExam, it is 45mm, representing an increase of 28%.


1. Based on internal data. E431R020.1.
2. E. Bardou-Jacquet et al. Validation of the Continuous Controlled Attenuation Parameter (CAPc) using the MRI-PDFF as reference. EASL 2022 poster #FRI-228.

The FibroScan® device (Models: 430 Mini+, 530 Compact and 630 Expert) is intended to measure liver stiffness (E) using Vibration Controlled Transient Elastography™ (VCTE™) at 50 Hz shear wave frequency and liver ultrasound attenuation coefficient (CAP™)* at 3.5 MHz. FibroScan® 630 Expert is also intended to measure spleen stiffness using VCTE™ at 100 Hz shear wave frequency. FibroScan liver stiffness measurements (LSM) by VCTE™ may aid the physician in determining the likelihood of cirrhosis and may be used, taken in context with other clinical and laboratory data, as an aid in the assessment of liver fibrosis. FibroScan CAP™ measurements may be used, taken in context with other clinical and laboratory data, as an aid in the assessment of hepatic steatosis. FibroScan® is indicated as a non-invasive aid for the clinical management, diagnosis, and monitoring of adult and pediatric patients with confirmed or suspected liver disease, as part of an overall assessment of the liver. Results in the pediatric population should be interpreted while considering the clinical condition and the overall patient profile. The FibroScan® device is intended for use by healthcare professionals in hospitals, clinics or any facility where healthcare is provided. *CAP™ refers to ultrasound attenuation coefficient (originally defined as Controlled Attenuation Parameter). CAP™ on S+ probe is only available with SmartExam capability. FibroScan® Gateway is a Non-Device Medical Device Data Systems (MDDS) and Interpretation Guide (included within myFibroScan application) are Non-Device Clinical Decision Support (CDS) that meet the criteria outlined in section 520(o)(1)(E) of the FD&C Act. © 2024 Echosens – Echosens™ and FibroScan® are trademarks owned by Echosens SA. All rights reserved. 

The Guided VCTE™ technology is only available on the latest FibroScan® systems and can be used only with M+ and XL+ probes.